Lessons from COVID-19: Impact on Healthcare Systems and Technology uncovers the impact that COVID-19 has made on healthcare and technology industries. State-of-the-art case studies, empirical research, and new trends in technology-mediated solution are discussed to help inform and guide readers in understanding the effects that the COVID-19 outbreak has had across healthcare and technology industries. The book discusses challenges to identify vaccines, changes in legislation on clinical trials and re-purposing of licensed drugs, effects on primary healthcare, best practices adopted by different countries to control the pandemic, and different effects on patients within diverse age groups and comorbidities. In addition, the book covers technology-mediated solutions and infrastructures applied, digital transformations, modeling techniques, statistical projections, and the benefits and use of cloud computing and artificial intelligence. This is a valuable resource for healthcare professionals, medical doctors, researchers and graduate students from both biomedical and technological fields who are interested in learning more about the use of new technologies to fight a pandemic.

Systems Evolutionary Biology: Biological Network Evolution Theory, Stochastic Evolutionary Game Strategies, and Applications to Systems Synthetic Biology discusses the evolutionary game theory and strategies of nonlinear stochastic biological networks under random genetic variations and environmental disturbances and their application to systematic synthetic biology design. The book provides more realistic stochastic biological system models to mimic the real biological systems in evolutionary process and then introduces network evolvability, stochastic evolutionary game theory and strategy based on nonlinear stochastic networks in evolution. Readers will find remarkable, revolutionary information on genetic evolutionary biology that be applied to economics, engineering and bioscience.

Therapeutic risk management of medicines is an authoritative and practical guide on developing, implementing and evaluating risk management plans for medicines globally. It explains how to assess risks and benefit-risk balance, design and roll out risk minimisation and pharmacovigilance activities, and interact effectively with key stakeholders.

A more systematic approach for managing the risks of medicines arose following a number of high-profile drug safety incidents and a need for better access to effective but potentially risky treatments. Regulatory requirements have evolved rapidly over the past decade. Risk management plans (RMPs) are mandatory for new medicinal products in the EU and a Risk Evaluation and Mitigation Strategy (REMS) is needed for certain drugs in the US.

This book is an easy-to-read resource that complements current regulatory guidance, by exploring key areas and practical implications in greater detail. It is structured into chapters encompassing a background to therapeutic risk management, strategies for developing RMPs, implementation of RMPs, and the continuing evolution of the risk management field.The topic is of critical importance not only to the pharmaceutical and biotechnology industries, but also regulators and healthcare policymakers.Some chapters feature contributions from selected industry experts.
An up-to-date practical guide on conceiving, designing, and implementing global therapeutic risk management plans for medicinesA number of useful frameworks are presented which add impact to RMPs (Risk Management Plans), together with regional specific information (European Union, United States, and Japan)Acomprehensive guide for performing risk management more effectively throughout a product s life-cycle"

This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the US and Europe. Before the orphan drug legislation enacted in the US in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups.
The journey from application of an orphan drug designation to a reimbursed market- approved drug is long and many obstacles occur during the journey.
After reading the book, readers will: Understand who the players/stakeholders are in the rare orphan disease field and their specific needs and concerns: patients and patient organizations, researchers and treating physicians within the field, industry, regulatory and reimbursement bodies* Understand the strong partnership between the different players and the various initiatives to improve and increase access to treatment for patients; minimizing the gap between numbers of known diseases, orphan designations, approved drugs and paid drugs.
The book also provides short practical case stories from patients and researchers, as well as representatives from industry and authorities on the challenges they came across in developing orphan drugs or getting access to orphan drugs.
A comprehensive overview of strategy, key activities and considerations of how to bring an orphan drug from concept to the market and make it available to patientsA source of updated information, news and trends for those who are already active in this fast-evolving fieldCovers the global definitions and the criteria for getting an orphan drug designation in, for example, the US and Europe

Research and development in the pharmaceutical industry is a time-consuming and expensive process, making it difficult for newly developed drugs to be formulated into commercially available products. Both formulation and process development can be optimized by means of statistically organized experiments, artificial intelligence and other computational methods. Simultaneous development and investigation of pharmaceutical products and processes enables application of quality by design concept that is being promoted by the regulatory authorities worldwide. Computer-aided applications in pharmaceutical technology covers the fundamentals of experimental design application and interpretation in pharmaceutical technology, chemometric methods with emphasis of their application in process control, neural computing (artificial neural networks, fuzzy logic and decision trees, evolutionary computing and genetic algorithms, self-organizing maps), computer-aided biopharmaceutical characterization as well as application of computational fluid dynamics in pharmaceutical technology. All of these techniques are essential tools for successful building of quality into pharmaceutical products and processes from the early stage of their development to selection of the optimal ones. In addition to theoretical aspects of various methods, the book provides numerous examples of their application in the field of pharmaceutical technology.
A comprehensive review of the current state of the art on various computer aided applications in pharmaceutical technologyCase studies are presented in order to facilitate understanding of various concepts in computer-aided applications

A biotech manager's handbook lays out - in a simple, straightforward manner - for the manager or would-be entrepreneur the basic principles of running a biotech company. Most managers in biotechnology companies are working in their first company or in their first managerial role. Their expertise and experience in the scientific part of the work can be taken as a given but there is a whole range of other skills to be learned and areas of expertise to come to terms with. Small companies do not have big budgets to hire people or time to become an expert in so many areas. The book starts by outlining the state of the biopharmaceutical industry and goes on to explain the importance of planning (no matter what the size of the company). Succeeding chapters deal with the basics of intellectual property, perspectives from a university technology transfer office and how to raise some initial funding from an investor and entrepreneur.
No other 'how to' manual exists for this sectorWritten by a range of expert professionals in each area, all in one bookIs the only 'bench to bedside' book covering the whole spectrum of development

This book analyses how China s firms in the consumer electronics (CE) sector have developed their business strategy and corporate governance during the reform process. The CE sector is one of China s most important and dynamic manufacturing sectors. As one of the earliest market-oriented sectors after 1978, its experience illustrates the adoption of the Western model of management in China. This is the first book to analyse the link between business strategy, corporate governance and performance of firms, explicitly comparing state-, collective-, and privately-owned firms. This book argues that the competitive dynamics of the market are central to the survival of firms in contemporary China.
Focuses on the state, collective and private Chinese firms in the consumer electronics sectorProvides insights into the interactions among political, economic and corporate factors in the China business environment that influence the strategies and performance of these firmsCompares the corporate governance of these Chinese firms across different ownership forms"

In this thoroughly updated second edition, Matthias Herdegen provides a comprehensive and contemporary assessment of the regulation of biotechnology processes and products from an international and comparative perspective, complete with analysis of intricate legal and ethical debates. Considering recent advances in biotechnology, this new edition explores how regulatory approaches to controversial issues such as stem cell research, cloning and gene therapy differ across jurisdictions due to conflicting values and risk perceptions. Reflecting on current developments, the book explores the interaction between biotechnology and different fields of law, including: human rights, intellectual property, trade law and environmental law. In doing so, Herdegen investigates complex concerns such as balancing commercial interests with socio-cultural considerations and ensuring respect for human dignity in the pursuit of biomedical research. Furthermore this new edition includes examination of recent developments in areas such as genome editing, biomedicine, COVID-19 vaccines, and patents on essentially biological products, with an entirely revised section on biobanks. Providing a concise and accessible guide to a complex field of international law, this book will be of great value to those researching the law and regulation of biotechnology, biomedicine and biodiversity both within the EU and at an international level. Practicing lawyers will also benefit from a diverse array of sources from a range of legal systems.

This book examines patent law and policy in biotechnology across the full lifecycle of the patent, focusing on the patent bargain and the public interest. It considers the central issues of how to strike an effective balance of rights, and whether public interest is adequately safeguarded - two issues that are particularly important in areas of rapidly emerging technology. Expert contributors are brought together to explore patent eligibility in biotechnology, focusing on the fields of precision medicine, biofabrication and non-invasive prenatal testing. Chapters also explore the construction and coherence of exceptions to patentability,an examination of FRAND licensing in the context of the internet of medical things, and the possibility of using licensing to encourage or ensure the ethical use of patented technologies. With its carefully constructed analysis, this book will be an excellent resource for academic researchers, and students, in the fields of biotechnology law, pharmaceutical law and intellectual property law. It will also be useful for legal practitioners and policymakers, as well as charitable bodies and non-governmental organisations.

To understand technological dependence and self-reliance in the manufacturing industries of the Third World, Sahu tests the main propositions of the two theories on technology transfer. He focuses particularly on understanding the shifting bargaining power of the multinationals, the state and private national capital; the process of acquisition, assimilation, adaptation, and generation of technology at the firm level; the role of the public sector and state regulations and control in the development of technological capability and self-reliant development; the conditions—domestic and international—that allow a developing country to move from a situation of dependency to self-reliance; and the phenomenon of reverse flow of technology from the Third World. According to Sahu, dependency theory is inadequate because of its structural mode of analysis, which portrays dependency as a determinant international structure rather than as a set of shifting constraints within which states seek to maneuver. Though its single-cause explanation of technological dependence in the Third World is helpful in explaining the phenomenon of the technological gap between India and its technology suppliers, it does not explain the growing bargaining power of the state and the national capital vis-a-vis multinationals in the last two decades. But according to Professor Sahu, the more sophisticated and dynamic bargaining framework, which considers dependency to be one of the many possible outcomes of technology transfer, helps researchers better understand the changing situations of developing countries, particularly the Indian situation since the early 1970s. An important study for researchers and policy makers dealing with economic development in emerging markets, particularly India.

Biotechnology is a field that inspires complex legal and ethical debates on an international scale. Taking a fresh approach to the subject, Matthias Herdegen provides a comprehensive assessment of the regulation of biotechnology processes and products from an international and comparative perspective. Herdegen explores how regulatory approaches to controversial issues such as: stem cell research and cloning and gene therapy differ across jurisdictions due to conflicting values and risk perceptions. The book goes on to examine how international regulatory instruments aim to address these conflicting perspectives and provide judgments based on broad international consensus. Chapters explore the interaction between biotechnology and different fields of law including: human rights, intellectual property, trade law and environmental law. In doing so, a number of complex issues are raised such as the need to balance commercial interests with socio-cultural considerations and the need to ensure respect for human dignity in the pursuit of biomedical research. Providing a concise and accessible guide to a complex field of international law, this book will be of great value to those researching the law and regulation of biotechnology, biomedicine and biodiversity both within the EU and on an international scale. The book will also be a useful resource for practicing lawyers as it includes sources from a diverse range of legal systems and analyses relevant decisions by international adjudicatory bodies.

Transcultural Artificial Intelligence and Robotics in Health and Social Care provides healthcare professionals with a deeper understanding of the incredible opportunities brought by the emerging field of AI robotics. In addition, it provides robotic researchers with the point-of-view of healthcare professionals to understand what the healthcare sector - as well as the market - really needs from robotics technology. By doing so, the book fills an important gap between both fields in order to leverage new developments and collaborative work in favor of global patients. The book is aimed at the non-technical reader, especially health and social care professionals, and explains in a simple way the technological principles applied in the development of socially assistive humanoid AI robots (SAHR), the values which guide such developments, the ethics related to them, and research approaches in the field, with a focus on achieving a culturally competent SAHR.

Roadmap to Successful Digital Health Ecosystems: A Global Perspective presents evidence-based solutions found on adopting open platforms, standard information models, technology neutral data repositories, and computable clinical data and knowledge (ontologies, terminologies, content models, process models, and guidelines), resulting in improved patient, organizational, and global health outcomes. The book helps engaging countries and stakeholders take action and commit to a digital health strategy, create a global environment and processes that will facilitate and induce collaboration, develop processes for monitoring and evaluating national digital health strategies, and enable learnings to be shared in support of WHO's global strategy for digital health. The book explains different perspectives and local environments for digital health implementation, including data/information and technology governance, secondary data use, need for effective data interpretation, costly adverse events, models of care, HR management, workforce planning, system connectivity, data sharing and linking, small and big data, change management, and future vision. All proposed solutions are based on real-world scientific, social, and political evidence.

Bioinformatics for Everyone provides a brief overview on currently used technologies in the field of bioinformatics-interpreted as the application of information science to biology- including various online and offline bioinformatics tools and softwares. The book presents valuable knowledge in a simplified way to help students and researchers easily apply bioinformatics tools and approaches to their research and lab routines. Several protocols and case studies that can be reproduced by readers to suit their needs are also included.

Micro and Nano Systems for Biophysical Studies of Cells and Small Organisms provides a comprehensive introduction to the state-of-the-art micro and nano systems that have recently been developed and applied to biophysical studies of cells and small organisms. These micro and nano systems span from microelectromechanical systems (MEMS) and microfluidic devices to robotic micro-nanomanipulation systems. These biophysical studies range from cell mechanics to the neural science of worms and Drosophila. This book will help readers understand the fundamentals surrounding the development of these tools and teach them the most recent advances in cellular and organismal biophysics enabled by these technologies.

The Electronic Health Record: Ethical Considerations analyses the ethical issues that surround the construction, maintenance, storage, use, linkage, manipulation and communication of electronic health records. Its purpose is to provide ethical guidance to formulate and implement policies at the local, national and global level, and to provide the basis for global certification in health information ethics. Electronic health records (EHRs) are increasingly replacing the use of paper-based records in the delivery of health care. They are integral to providing eHealth, telehealth, mHealth and pHealth - all of which are increasingly replacing direct and personal physician-patient interaction - as well as in the developing field of artificial intelligence and expert systems in health care. The book supplements considerations that are raised by national and international regulations dealing with electronic records in general, for instance the General Data Protection Regulation of the European Union. This book is a valuable resource for physicians, health care administrators and workers, IT service providers and several members of biomedical field who are interested in learning more about how to ethically manage health data.

Now with a new afterword covering the months-long landmark trials of Elizabeth Holmes and Sunny Balwani. ‘I couldn’t put down this thriller . . . the perfect book to read by the fire this winter.’ Bill Gates Winner of the Financial Times/McKinsey Business Book of the Year Award 2018 The riveting true story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup founded by Elizabeth Holmes, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup ‘unicorn’ promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.7 billion. There was just one problem: the technology didn’t work. In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley. ‘Chilling . . . Reads like a West Coast version of All the President’s Men.’ New York Times Book Review

Single-Cell Omics: Volume 1: Technological Advances and Applications provides the latest technological developments and applications of single-cell technologies in the field of biomedicine. In the current era of precision medicine, the single-cell omics technology is highly promising due to its potential in diagnosis, prognosis and therapeutics. Sections in the book cover single-cell omics research and applications, diverse technologies applied in the topic, such as pangenomics, metabolomics, and multi-omics of single cells, data analysis, and several applications of single-cell omics within the biomedical field, for example in cancer, metabolic and neuro diseases, immunology, pharmacogenomics, personalized medicine and reproductive health. This book is a valuable source for bioinformaticians, molecular diagnostic researchers, clinicians and members of the biomedical field who are interested in understanding more about single-cell omics and its potential for research and diagnosis.

New Horizons in Natural Compound Research provides the latest updates in natural compound research (plant, microbes, algae, fungi) and their novel applications in health, agriculture and environment. The book gives recent advances in the extraction of natural compounds, cutting-edge approaches for natural compound purifications, and emerging trends in natural compound screening and identification. In addition, it provides a detailed explanation of the databases and libraries of natural compounds, as well as their significance. Sections focus on research and multidisciplinary practical techniques of natural product research, encouraging young scientists to pursue unique research while also generating strong research ideas. From a future perspective, this book acts as a guide to identify potential areas and new research opportunities in the field of natural products and their service towards human beings, animals and the environment.

Fruit Breeding is an art and science demanding prolonged time, space and intrinsic qualities. Seed propagation leads to heterogeneity and asexual propagation of elite clones' leads to newer and novel types. There are temperate, sub-tropical and tropical fruits differing in photo and thermo periodic requirements. There are also parthenocarpic and apomictic fruit trees demanding special breeding methods for improvement. Aroma, taste and flavor are unique to fruits unlike other horticultural crops like vegetables, spices, plantation crops and tubers. The book unravels history of fruit breeding, biodiversity, challenges approaches and prospects, apomixes, mutation breeding, role of insects in fruit production, molecular markers, statistical techniques, rootstock breeding, breeding of mango, citrus, banana, papaya, guava, sapota, jackfruit, sugarapple/sweetsop Indian jujube and jamun. The 20 s in the book authored by 15 scientists from six Research Institutes and Universities expose readers to a new world of fruit breeding, very seldom ventured by breeders.

Cashew (Anacardium occidentale L. f. Anacardiaceae) is very important and dollar earning plantation crop. A systematic compilation on various aspects has been covered in this book. It consists the s viz. Introduction; History, origin and geographical distribution; Area, production, productivity, export and import; Soil and climate; Biodiversity and crop improvement; Varieties; Propagation and production of planting material; Morphology and tree characters; Pollination techniques; Establishments of cashew orchard; Mineral nutrition; Training and pruning; Rejuvenation of old orchards; Inter-cropping and cover cropping; Intercultural operation; Maturity, harvesting and yield; Post harvest storage; Marketing of raw nuts; Nutritive value of cashew; Cashew nut processing; Cashew apple processing; Pests and diseases; Economics for cashew cultivation; Future strategies along with references. This book will be helpful to students and teachers of horticulture, agriculture and forestry, scientists, researchers, cashew growers and processors including small scale processing unit holders.

The objective of this book is to provide state-of-the-art knowledge, and highlight the current developments taking place in biological sciences. The book encompasses topics on prokaryotic cyanobacteria to higher plants, distributed in fourteen s for the benefit of graduate and post-graduate students as well as young researchers and scientists. Subjects covered include molecular and biochemical diversity of microbes, stress biology, cyanotoxins, antimicrobial activity of drugs originated from plants, natural bioactive compounds of microbial origin, detection approaches for genetically modified crops, genomics and proteomics. The book provides an insight for future perspectives in particular field with extensive bibliographies at the end of each . With all these, this book becomes highly useful and must-read for students, researchers and professionals in botany, biotechnology, bioinformatics, environmental sciences, agriculture, molecular biology and other streams of biological sciences.

The COVID-19 pandemic has affected the entire world in an unprecedented way since 2019. However, novel and innovative applications of various omics, computational, and smart technologies have helped manage the pandemic of the 21st century in a very effective manner. Omics approaches and technologies in COVID-19 presents up-to-date knowledge on omics, genetic engineering, mathematical and computational approaches, and advanced technologies in the diagnosis, prevention, monitoring, and management of COVID-19. This book contains 26 chapters written by academic and industry experts from more than 15 countries. Split into three sections (Omics; Artificial Intelligence and Bioinformatics; and Smart and Emerging Technologies), it brings an overview of novel technologies under omics such as, genomic, metagenomic, pangenomic, metabolomics and proteomics in COVID-19. In addition, it discusses hostpathogen interactions and interactomics, management options, application of genetic engineering, mathematical modeling and simulations, systems biology, and bioinformatics approaches in COVID-19 drug discovery and vaccine development. This is a valuable resource for students, biotechnologists, bioinformaticians, virologists, clinicians, and pharmaceutical, biomedical, and healthcare industry people who want to understand the promising omics and other technologies used in combating COVID-19 from various aspects.

The emergence of platforms is a novel phenomenon impacting most industries, from products to services. Industry platforms such as Microsoft Windows or Google, embedded within industrial ecosystems, have redesigned our industrial landscapes, upset the balance of power between firms, fostered innovation and raised new questions on competition and innovation. Annabelle Gawer presents cutting-edge contributions from 24 top international scholars from 19 universities across Europe, the USA and Asia, from the disciplines of strategy, economics, innovation, organization studies and knowledge management. The novel insights assembled in this volume constitute a fundamental step towards an empirically based, nuanced understanding of the nature of platforms and the implications they hold for the evolution of industrial innovation. The book provides an overview of platforms and discusses governance, management, design and knowledge issues. With a multidisciplinary approach, this book will strongly appeal to academics and advanced students in management, innovation, strategy, economics and design. It will also prove an enlightening read for business managers in IT industries.

Novel AI and Data Science Advancements for Sustainability in the Era of COVID-19 discusses how the role of recent technologies applied to health settings can help fight virus outbreaks. Moreover, it provides guidelines on how governments and institutions should prepare and quickly respond to drastic situations using technology to support their communities in order to maintain life and functional as efficiently as possible. The book discusses topics such as AI-driven histopathology analysis for COVID-19 diagnosis, bioinformatics for subtype rational drug design, deep learning-based treatment evaluation and outcome prediction, sensor informatics for monitoring infected patients, and machine learning for tracking and prediction models. In addition, the book presents AI solutions for hospital management during an epidemic or pandemic, along with real-world solutions and case studies of successful measures to support different types of communities. This is a valuable source for medical informaticians, bioinformaticians, clinicians and other healthcare workers and researchers who are interested in learning more on how recently developed technologies can help us fight and minimize the effects of global pandemics.